AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib & Nivolumab (OPDIV...
October 09 2018 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that updated interim
data from the Phase 2 portion of the TiNivo trial of tivozanib and
nivolumab (OPDIVO®) in advanced renal cell carcinoma will be
presented at the European Society of Medical Oncology (ESMO) 2018
Annual Congress being held October 19-23, 2018 in Munich, Germany.
The TiNivo study is a Phase 1b/2 multicenter trial of oral
tivozanib (FOTIVDA®) in combination with intravenous nivolumab
(OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1,
inhibitor, for the treatment of metastatic renal cell carcinoma
(mRCC).
The accepted abstract, which includes results from a poster
presentation at the 2018 American Society of Clinical Oncology
(ASCO) Gastrointestinal Cancers Symposium in January, is available
via the ESMO 2018 Annual Congress website. Updated data will be
presented at the ESMO conference.
Presentation Details
Title: TiNivo: Tivozanib combined with nivolumab: safety
and efficacy in patients with metastatic renal cell carcinoma
(mRCC)Presenter: Philippe Barthelemy, Medical Oncology
Department, Hôpitaux Universitaires de Strasbourg, Strasbourg,
FRPresentation Number: 878PDate and Time: October 22,
2018, 1:05 p.m. CESTLocation: Hall A3 - Poster Area
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company”) is a
biopharmaceutical company dedicated to advancing a broad portfolio
of targeted medicines for oncology and other areas of unmet medical
need. The Company’s strategy is to retain North American rights to
its oncology portfolio while securing partners in development and
commercialization outside of North America. The Company is seeking
to develop and commercialize its lead candidate tivozanib in North
America as a treatment for advanced renal cell carcinoma (“RCC”).
The Company has outlicensed tivozanib (FOTIVDA®) for oncology in
Europe and other territories outside of North America. Tivozanib is
approved in the European Union, as well as Norway and Iceland, for
the first-line treatment of adult patients with RCC and for adult
patients who are vascular endothelial growth factor receptor and
mTOR pathway inhibitor-naïve following disease progression after
one prior treatment with cytokine therapy for RCC. The Company has
entered into partnerships for the development and commercialization
of AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in
oncology. The Company is currently seeking a partner to develop the
AV-353 platform, a preclinical asset, worldwide for the potential
treatment of pulmonary arterial hypertension. The Company has
recently regained the rights to its AV-380 program for the
potential treatment of cachexia and is considering a variety of
options to advance the program’s development.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. The words “anticipate,”
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “could,”
“should,” “would,” “seek,” “look forward,” “advance,” “goal,”
“strategy,” or the negative of these terms or other similar
expressions, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among
others, statements about: the Company’s plans and strategies for
commercialization of tivozanib in the United States and Europe; the
potential for tivozanib to have clinical potential in immunotherapy
combinations; creating an evidence-based guidepost for sequencing
therapies in refractory disease; the Company’s plan to seek a
partner to develop the AV-353 platform; the Company’s plans
regarding AV-380 and AVEO’s strategy, prospects, plans and
objectives. AVEO has based its expectations and estimates on
assumptions that may prove to be incorrect. As a result, readers
are cautioned not to place undue reliance on these expectations and
estimates. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements that AVEO makes due to a number of
important factors, including risks relating to AVEO’s ability to
enter into and maintain its third party collaboration and license
agreements, and its ability, and the ability of its collaborators,
licensees and other strategic partners, to achieve development and
commercialization objectives under these arrangements; and AVEO’s
ability, and the ability of its licensees, to demonstrate to the
satisfaction of applicable regulatory agencies such as the FDA the
safety, efficacy and clinically meaningful benefit of AVEO’s
product candidates, including tivozanib. AVEO faces other risks
relating to its business as well, including risks relating to its
and its collaborators’ ability to successfully enroll and complete
clinical trials, including the TIVO-3 and TiNivo studies; AVEO’s
ability to achieve and maintain compliance with all regulatory
requirements applicable to its product candidates; AVEO’s ability
to obtain and maintain adequate protection for intellectual
property rights relating to its product candidates and
technologies; AVEO’s ability to successfully implement its
strategic plans; AVEO’s ability to raise the substantial additional
funds required to achieve its goals, including those goals
pertaining to the development and commercialization of tivozanib;
unplanned capital requirements; adverse general economic and
industry conditions; competitive factors; and those risks discussed
in the section titled “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations,
Liquidity and Capital Resources” included in AVEO’s quarterly and
annual reports on file with the Securities and Exchange Commission
(SEC) and in other filings that AVEO may make with the SEC in the
future. The forward-looking statements in this press release
represent AVEO’s views as of the date of this press release. AVEO
anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing AVEO's views as of any date other than the date of
this press release. Any reference to AVEO’s website address in this
press release is intended to be an inactive textual reference only
and not an active hyperlink.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181009005370/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024